MAR 04, 2016 8:13 AM PST

New Antiviral Drug Beats Ebola Virus in Monkey Trials

WRITTEN BY: Xuan Pham
Ebola virus

A new small-molecule drug was recently shown to protect Rhesus monkeys from the Ebola virus, decreasing viral loads significantly and resulting in 100% survival of the monkeys. This compound was also shown to successfully treat 2 human Ebola patients for whom the drug was given for compassionate use. These results make the compound GS-5734 a likely pharmaceutical candidate for Ebola treatment.
 
Ebola infection and transmission caused a huge international health crisis in 2015 in West Africa, the site of the largest outbreak in history. The virus causes severe hemorrhagic fevers that lead to high mortality rates, since there are no licensed vaccines or therapies against this virus. While the outbreak is currently under control, there’s no guarantee that such event won’t be repeated. As such, research into possible Ebola treatment is imperative.
 
 
The small-molecule compound is described as a nucleotide analog prodrug, inhibiting the incorporation of the adenosine base in the viral DNA. This effectively “blocks the virus's ability to replicate its own genetic material,” said first study author, Travis Warren. "With this process inhibited, the virus can't make copies of itself. Additionally, we saw no evidence from genetic sequence analyses that the virus was able to generate resistance to GS-5734," he added.
 
In Rhesus monkeys treated with the GS-5734 compound within 3 days after infection, the researchers noticed remission of physical Ebola symptoms and decreased viral load count. Remarkably, these treated monkeys showed 100% survival after infection, showing promising evidence of the efficacy of this drug.
 
GS-5734 has also shown to be effective in cells grown on laboratory dishes. In these systems, the compound was active against a broad spectrum of viral pathogens, including multiple strains of the Ebola virus, as well as Middle East Respiratory Syndrome (MERS) virus, and Marburg virus. These additional results could extend the application of the compound to treating multiple other viral-associated diseases.
 
"GS-5734 has several favorable characteristics for potential treatment of Ebola virus disease in humans. It is made using well-controlled chemical synthesis procedures, is stable, and can be made on a large scale," said Sina Bavari, senior study author. "It shows substantive post-exposure protection against Ebola virus in nonhuman primates, even when treatments were started after virus had spread to the blood in some animals."
 
The research team is excited at the prospects of conducting further testing on this compound. Already, Gilead Sciences, a prominent collaborator in this study, is conducting a phase I clinical trial with GS-5734 to determine safety and pharmacokinetic properties in healthy human patients.
 
In two instances where the compound was given to patients for compassionate use, both patients recovered fully and were discharged from the hospitals. How GS-5734 played a role in the recovery will be extensively studied in the future.
 
Additional source: Nature journal,  Science Daily
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 09, 2021
Cell & Molecular Biology
CRISPR-SNP Chip Finds Point Mutations in DNA Without PCR
APR 09, 2021
CRISPR-SNP Chip Finds Point Mutations in DNA Without PCR
Some diseases, like sickle-cell anemia and familial amyotrophic lateral sclerosis are due to errors in only a single let ...
APR 27, 2021
Clinical & Molecular DX
No Batteries: Health Sensor Harvests Biomechanical Energy
APR 27, 2021
No Batteries: Health Sensor Harvests Biomechanical Energy
An international team of researchers has developed a wearable health monitor that works without the need for batteries. ...
MAY 09, 2021
Genetics & Genomics
Another Neurodevelopmental Disorder is Discovered
MAY 09, 2021
Another Neurodevelopmental Disorder is Discovered
Researchers are identifying more rare disorders because of advances in genetic sequencing technologies, which have made ...
AUG 05, 2021
Clinical & Molecular DX
Wearable Patch Senses Blood Vessel Blockages
AUG 05, 2021
Wearable Patch Senses Blood Vessel Blockages
The cardiovascular system is like a network of highways, filled with an estimated 25 trillion red blood cells that conti ...
AUG 10, 2021
Drug Discovery & Development
Epidemiology and postexposure prophylaxis of rabies virus
AUG 10, 2021
Epidemiology and postexposure prophylaxis of rabies virus
Rabies is a viral disease that can be transmitted from an infected animal to another animal or human. In the U ...
SEP 14, 2021
Health & Medicine
The Magnitude of Cardiovascular Disease- New Insights and Ways Forward
SEP 14, 2021
The Magnitude of Cardiovascular Disease- New Insights and Ways Forward
Among healthcare professionals, it is common knowledge that cardiovascular disease is the leading cause of death in the ...
Loading Comments...